Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRXNASDAQ:NBIXNYSE:NVSNASDAQ:PLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$23.92-1.4%$22.71$14.47▼$26.16$2.91B0.841.12 million shs1.28 million shsNBIXNeurocrine Biosciences$107.00-3.3%$122.73$105.18▼$157.98$10.67B0.35986,446 shs1.74 million shsNVSNovartis$109.49-1.8%$108.40$92.35▼$120.92$223.80B0.531.50 million shs1.95 million shsPLRXPliant Therapeutics$1.37+1.5%$4.42$1.24▼$16.52$83.89M1.181.02 million shs3.09 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals-1.36%-7.00%+4.50%+14.61%+51.97%NBIXNeurocrine Biosciences-3.25%-7.90%-9.87%-21.61%-24.32%NVSNovartis-1.79%-0.74%+0.40%+12.52%+14.22%PLRXPliant Therapeutics+1.48%-8.05%-60.17%-89.60%-90.75%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.8252 of 5 stars4.61.00.03.92.73.32.5NBIXNeurocrine Biosciences4.9203 of 5 stars4.43.00.02.93.52.53.1NVSNovartis3.1298 of 5 stars1.95.02.50.04.00.01.9PLRXPliant Therapeutics4.2053 of 5 stars4.02.00.04.71.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.13Buy$32.2934.97% UpsideNBIXNeurocrine Biosciences 2.83Moderate Buy$165.3854.56% UpsideNVSNovartis 1.80Reduce$123.3812.68% UpsidePLRXPliant Therapeutics 2.00Hold$13.31871.72% UpsideCurrent Analyst Ratings BreakdownLatest PLRX, NVS, CPRX, and NBIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025NBIXNeurocrine BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$183.00 ➝ $184.003/18/2025PLRXPliant TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/7/2025NBIXNeurocrine BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$185.00 ➝ $150.003/4/2025PLRXPliant TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $1.503/4/2025PLRXPliant TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/4/2025PLRXPliant TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $3.003/4/2025PLRXPliant TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral3/4/2025PLRXPliant TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$4.00 ➝ $3.003/4/2025PLRXPliant TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$10.00 ➝ $10.003/3/2025CPRXCatalyst PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $32.003/3/2025PLRXPliant TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M5.91$2.23 per share10.72$3.30 per share7.25NBIXNeurocrine Biosciences$2.36B4.53$3.11 per share34.35$25.97 per share4.12NVSNovartis$51.72B4.33$10.92 per share10.03$21.59 per share5.07PLRXPliant Therapeutics$1.58M53.10N/AN/A$7.91 per share0.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$71.41M$1.3120.2711.233.3131.01%40.79%34.87%5/6/2025 (Estimated)NBIXNeurocrine Biosciences$341.30M$3.2932.5216.540.7714.49%13.38%9.73%4/29/2025 (Estimated)NVSNovartis$11.94B$5.8818.6212.431.7023.56%37.24%15.85%4/22/2025 (Estimated)PLRXPliant Therapeutics-$161.34M-$3.47N/AN/AN/AN/A-48.91%-41.09%5/5/2025 (Estimated)Latest PLRX, NVS, CPRX, and NBIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/22/2025N/ANVSNovartis$2.07N/AN/AN/AN/AN/A3/3/2025Q4 2024PLRXPliant Therapeutics-$0.99-$0.82+$0.17-$0.82$0.08 millionN/A2/6/2025Q4 2024NBIXNeurocrine Biosciences$1.62$1.00-$0.62$1.00$629.40 millionN/A1/31/2025Q4 2024NVSNovartis$1.80$1.98+$0.18$1.41$12.86 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ANBIXNeurocrine BiosciencesN/AN/AN/AN/AN/ANVSNovartis$2.512.29%+5.34%42.69%N/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ALatest PLRX, NVS, CPRX, and NBIX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/20/2025NVSNovartis$3.86953/12/20253/12/20253/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A5.114.92NBIXNeurocrine BiosciencesN/A3.403.28NVSNovartis0.481.040.84PLRXPliant Therapeutics0.0910.2610.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%NBIXNeurocrine Biosciences92.59%NVSNovartis13.12%PLRXPliant Therapeutics97.30%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals11.00%NBIXNeurocrine Biosciences4.30%NVSNovartis0.01%PLRXPliant Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80121.45 million106.15 millionOptionableNBIXNeurocrine Biosciences1,20099.70 million95.42 millionOptionableNVSNovartis101,7002.04 billion2.04 billionOptionablePLRXPliant Therapeutics9061.24 million56.96 millionOptionablePLRX, NVS, CPRX, and NBIX HeadlinesRecent News About These CompaniesWhy Pliant Therapeutics, Inc.’s (PLRX) Stock Is Down 10.89%March 31 at 11:29 PM | aaii.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 28, 2025 | prnewswire.comBiomea Fusion (NASDAQ:BMEA) vs. Pliant Therapeutics (NASDAQ:PLRX) Head-To-Head SurveyMarch 28, 2025 | americanbankingnews.comPLRX Stock Plunges 89% in 3 Months: Here's What Investors Should KnowMarch 27, 2025 | zacks.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRXMarch 26, 2025 | globenewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 23, 2025 | globenewswire.comPliant discontinues Phase 2b/3 trial of IPF treatment bexotegrastMarch 21, 2025 | pulmonaryfibrosisnews.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - PLRXMarch 21, 2025 | markets.businessinsider.comPliant Therapeutics (NASDAQ:PLRX) Receives Neutral Rating from HC WainwrightMarch 19, 2025 | marketbeat.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 19, 2025 | globenewswire.comWhy Pliant Therapeutics, Inc.’s (PLRX) Stock Is Up 10.39%March 18, 2025 | aaii.comPliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor TypesMarch 18, 2025 | benzinga.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 18, 2025 | markets.businessinsider.comPliant Therapeutics announces interim Phase 1 data from PLN-101095March 17, 2025 | markets.businessinsider.comPliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid TumorsMarch 17, 2025 | globenewswire.comINVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 16, 2025 | accessnewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 15, 2025 | globenewswire.comPliant Pops Poison Pill as Concentra Threat LoomsMarch 14, 2025 | biospace.comPliant, Acelyrin resort to ‘poison pills’ as threat of Concentra buyout loomsMarch 14, 2025 | fiercebiotech.comPliant Therapeutics, Inc.: Pliant Therapeutics Adopts Limited Duration Stockholder Rights AgreementMarch 13, 2025 | finanznachrichten.deSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 13, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLRX, NVS, CPRX, and NBIX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$23.92 -0.33 (-1.36%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$23.98 +0.05 (+0.23%) As of 04/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Neurocrine Biosciences NASDAQ:NBIX$107.00 -3.60 (-3.25%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$106.99 -0.01 (-0.01%) As of 04/1/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Novartis NYSE:NVS$109.49 -1.99 (-1.78%) Closing price 04/1/2025 03:59 PM EasternExtended Trading$109.30 -0.19 (-0.17%) As of 04/1/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Pliant Therapeutics NASDAQ:PLRX$1.37 +0.02 (+1.48%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$1.38 +0.00 (+0.36%) As of 04/1/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
